Literature DB >> 2651650

The ocular route for systemic insulin delivery in the albino rabbit.

A Yamamoto1, A M Luo, S Dodda-Kashi, V H Lee.   

Abstract

The objective of this study was to determine the extent, pathways and effects of absorption promoters on the systemic absorption of insulin after topical solution instillation to the albino rabbit eye. The absorption promoters were polyoxyethylene-9-lauryl ether, Na glycocholate (GC), Na taurocholate and Na deoxycholate, all at a concentration of 1%. Plasma glucose concentration was measured in a glucose analyzer whereas plasma insulin concentration was measured using radioimmunoassay. The systemic bioavailability of insulin calculated from its area under concentration-time curve was in good agreement with that derived from the glucose concentration-time curve. The bioavailability was 5.7 to 12.6% with polyoxyethylene-9-lauryl ether, 4.9 to 7.9% with GC, 3.6 to 7.8% with Na taurocholate and 8.2 to 8.3% with Na deoxycholate, as compared to 0.7 to 1.3% in the absence of absorption promoters. The absorption promoting effect of GC was dependent on its concentration over the range of 0.1 to 2%. At 1%, the absorption promoting effect of GC persisted for about 5 min but disappeared by 15 to 30 min. The nasal mucosa contributed about 4 times more than the conjunctival mucosa to the systemic absorption of ocularly applied insulin. The conjunctival mucosa was, however, more discriminant in its sensitivity to the nature of the bile salts than the nasal mucosa. The former was most sensitive to Na deoxycholate and least to Na taurocholate. Collectively, our findings indicate that it is feasible to obtain hypoglycemia from ocularly administered insulin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2651650

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Recent developments in insulin delivery techniques. Current status and future potential.

Authors:  F P Kennedy
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

2.  Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats.

Authors:  A Yamamoto; T Taniguchi; K Rikyuu; T Tsuji; T Fujita; M Murakami; S Muranishi
Journal:  Pharm Res       Date:  1994-10       Impact factor: 4.200

Review 3.  Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents.

Authors:  M Mikov; J P Fawcett; K Kuhajda; S Kevresan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Jul-Sep       Impact factor: 2.441

4.  Conjunctival penetration of insulin and peptide drugs in the albino rabbit.

Authors:  E Hayakawa; D S Chien; K Inagaki; A Yamamoto; W Wang; V H Lee
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

5.  Improvement of the pulmonary absorption of (Asu1,7)-eel calcitonin by various protease inhibitors in rats.

Authors:  T Morita; A Yamamoto; Y Takakura; M Hashida; H Sezaki
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

6.  Noninvasive routes of proteins and peptides drug delivery.

Authors:  P K Sharma; Sumedha Bansal; Arunabha Banik
Journal:  Indian J Pharm Sci       Date:  2011-07       Impact factor: 0.975

7.  Formulation development, in vitro and in vivo evaluation of chitosan engineered nanoparticles for ocular delivery of insulin.

Authors:  Priyanka Rathore; Alok Mahor; Surendra Jain; Anzarul Haque; Prashant Kesharwani
Journal:  RSC Adv       Date:  2020-12-08       Impact factor: 4.036

8.  Preparation and Evaluation of Mucus-Penetrating Inhalable Microparticles of Tiotropium Bromide Containing Sodium Glycocholate.

Authors:  Yong-Bin Kwon; Ji-Hyun Kang; Young-Jin Kim; Dong-Wook Kim; Sung-Hoon Lee; Chun-Woong Park
Journal:  Pharmaceutics       Date:  2022-07-05       Impact factor: 6.525

9.  Prevention of Postprandial Hyperglycemia by Ophthalmic Nanoparticles Based on Protamine Zinc Insulin in the Rabbit.

Authors:  Saori Deguchi; Fumihiko Ogata; Takumi Isaka; Hiroko Otake; Yosuke Nakazawa; Naohito Kawasaki; Noriaki Nagai
Journal:  Pharmaceutics       Date:  2021-03-12       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.